CA2430610A1 - Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases - Google Patents

Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases Download PDF

Info

Publication number
CA2430610A1
CA2430610A1 CA002430610A CA2430610A CA2430610A1 CA 2430610 A1 CA2430610 A1 CA 2430610A1 CA 002430610 A CA002430610 A CA 002430610A CA 2430610 A CA2430610 A CA 2430610A CA 2430610 A1 CA2430610 A1 CA 2430610A1
Authority
CA
Canada
Prior art keywords
protein
leu
gly
mif
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002430610A
Other languages
English (en)
French (fr)
Inventor
Birgit Jung
Stefan Muller
Norbert Kraut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2430610A1 publication Critical patent/CA2430610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
CA002430610A 2000-12-22 2001-12-15 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases Abandoned CA2430610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25787800P 2000-12-22 2000-12-22
US60/257,878 2000-12-22
PCT/EP2001/014838 WO2002052270A2 (en) 2000-12-22 2001-12-15 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Publications (1)

Publication Number Publication Date
CA2430610A1 true CA2430610A1 (en) 2002-07-04

Family

ID=22978162

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002430610A Abandoned CA2430610A1 (en) 2000-12-22 2001-12-15 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Country Status (6)

Country Link
US (1) US20020150958A1 (https=)
EP (1) EP1346228A2 (https=)
JP (1) JP2004516038A (https=)
CA (1) CA2430610A1 (https=)
MX (1) MXPA03005325A (https=)
WO (1) WO2002052270A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021360A1 (en) * 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU2002321229A1 (en) * 2001-08-06 2003-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying anti-inflammatory drugs
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
US20070037156A1 (en) * 2003-08-11 2007-02-15 Lovelace Respiratory Research Institute Metalloproteinase gene polymorphism in copd
WO2007044622A1 (en) 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
FR2904001A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la udp-glucose ceramide glucosyltransferase dans le traitement de l'acne ou de l'hyperkeratinisation
CA2893249A1 (en) * 2012-12-07 2014-06-12 Baxter International Inc. Anti-mif antibody cell migration assay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
WO2001032606A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity

Also Published As

Publication number Publication date
WO2002052270A3 (en) 2003-03-13
EP1346228A2 (en) 2003-09-24
WO2002052270A2 (en) 2002-07-04
JP2004516038A (ja) 2004-06-03
US20020150958A1 (en) 2002-10-17
MXPA03005325A (es) 2004-12-03

Similar Documents

Publication Publication Date Title
Ellerby et al. Shift of the cellular oxidation‐reduction potential in neural cells expressing Bcl‐2
Haendeler et al. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69
Abe et al. Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras
Barrientos In vivo and in organello assessment of OXPHOS activities
Vaux et al. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain
Shi et al. Involvement of vascular peroxidase 1 in angiotensin II-induced vascular smooth muscle cell proliferation
Geiszt et al. Chronic granulomatous disease: more than the lack of superoxide?
Ohta et al. Association with cullin partners protects ROC proteins from proteasome-dependent degradation
Leung-Pineda et al. Induction of p21 and p27 expression by amino acid deprivation of HepG2 human hepatoma cells involves mRNA stabilization
Hattori et al. Glycated serum albumin-induced vascular smooth muscle cell proliferation through activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by protein kinase C
US20030103965A1 (en) Method for identifying substances which positively influence inflammatory conditions
US20020150958A1 (en) Methods for identifying substances for treating inflammatory conditions
McFarlane et al. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses
Harry et al. Metabolic impact of 4-hydroxynonenal on macrophage-like RAW 264.7 function and activation
O'Donnell et al. Endothelial NADPH oxidase: mechanism of activation by low-density lipoprotein
IL196874A (en) Filtration method for operators of soluble guanylate cyclase with iron are oxidized
Li et al. Redox control of K+ channel remodeling in rat ventricle
Krysan et al. Regulation of human thioltransferase (hTTase) gene by AP-1 transcription factor under oxidative stress
Zangar et al. The nuclear factor-κB pathway regulates cytochrome P450 3A4 protein stability
Sarkar et al. Nitric oxide: not just a negative inotrope
Zenke et al. NF-κB p105-mediated nuclear translocation of ERK is required for full activation of IFNγ-induced iNOS expression
Joguchi et al. Overexpression of VDUP1 mRNA sensitizes HeLa cells to paraquat
Arnaud et al. Differences between apoplastic and cytosolic reactive oxygen species production in Arabidopsis during pattern-triggered immunity
US20020160438A1 (en) Method for identifying compounds which positively influence inflammatory conditions
RU2315305C2 (ru) Способ прогнозирования инфекционных осложнений после химиотерапии у больных острыми лейкозами

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead